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Whilehumanembryonicstemcells(hESCs)mayonedayfacilitatethetreatmentofdegenerativediseasesrequiringcellreplacement
therapy,thesuccessofregenerativemedicineispredicatedonovercomingtherejectionofreplacementtissues.Giventheroleplayed
by dendritic cells (DCs) in the establishment of immunological tolerance, we have proposed that DC, rendered tolerogenic during
their diﬀerentiation from hESC, might predispose recipients to accept replacement tissues. As a ﬁrst step towards this goal, we
demonstrate that DC diﬀerentiated from H1 hESCs (H1-DCs) are particularly responsive to the immunosuppressive agent rapa-
mycin compared to monocyte-derived DC (moDC). While rapamycin had only modest impact on the phenotype and function
of moDC, H1-DC failed to upregulate CD40 upon maturation and displayed reduced immunostimulatory capacity. Furthermore,
coculture of na¨ ıve allogeneic T cells with rapamycin-treated H1-DC promoted an increased appearance of CD25hi Foxp3+ regula-
toryTcells,comparedtomoDC.OurﬁndingssuggestthatconditioningofhESC-derivedDCwithrapamycinfavoursatolerogenic
phenotype.
1.Introduction
Human embryonic stem cells (hESCs) derived under condi-
tions compliant with their downstream clinical application,
serve as a renewable source of cell types that may one day en-
able the replacement of tissues whose function has become
compromised by chronic or degenerative disease [1]. Never-
theless, the routine implementation of cell replacement ther-
apy (CRT) requires strategies to address the immunological
barriers encountered by the use of hESC of allogeneic origin
[2]. While conventional immunosuppression oﬀers a poten-
tial solution to the immunogenicity of hESC-derived tissues,
the risks inherent in its protracted use make the induction of
transplantation tolerance an attractive alternative.
Dendritic cells (DCs) play a critical role in determining
the outcome of antigen presentation to naive T cells, either
promoting their activation and subsequent immunity, or
favouring the induction of tolerance [3]. The delivery of for-
eign antigen to DC in the steady state by conjugation to
monoclonalantibodies(mAbs)speciﬁcforthesurfacerecep-
tor CD205, was, for instance, found to render recipient mice
speciﬁcally tolerant to the antigen upon subsequent immu-
nization [4]. Such ﬁndings have been extended to a trans-
plantation setting by demonstrating how administration of
immature donor DC to mice across a minor histocompati-
bility barrier is suﬃcient to secure the indeﬁnite survival of
donorskingrafts.Inthismodel,theresultingtolerancecould
be attributed to the polarisation of responding T cells to-
wards a regulatory phenotype, characterised by upregulation
of the transcription factor Foxp3 [5]. Such ﬁndings, together
with early success at inducing tolerance in healthy human
volunteers by the administration of immature antigen-puls-
ed monocyte-derived DC (moDC) [6], augur well for the
future use of DC as a conditioning regime in the context
of CRT. Indeed, the recent description of protocols for the
diﬀerentiation of DC from hESC under conditions sub-
stantially free of animal products paves the way for such an
approach: given that this source of DC would share with2 Journal of Biomedicine and Biotechnology
the replacement tissue the very alloantigens to which toler-
ance must be established, their administration in advance of
CRTmightbeanticipatedtoconditiontherecipienttoaccept
the transplanted tissue, providing the DC have ﬁrst been
rendered stably tolerogenic [7]. Accordingly, Senju et al. gen-
erated DC expressing the inhibitory receptor programmed
death ligand 1 (PD-L1) by genetic modiﬁcation of the parent
hESC line [8], a similar approach in the mouse having suc-
cessfullyyieldedDCcapableofpreventingtheonsetofexper-
imental autoimmune encephalomyelitis by induction of tol-
erance to myelin antigens [9]. While such a strategy is clearly
promising,theadministrationofgeneticallymodiﬁedcellsto
patients poses additional regulatory barriers, suggesting that
exposure of DC to pharmacological agents, known to pro-
mote a tolerogenic phenotype, may prove to be a more prag-
matic approach [10].
The macrocyclic triene antibiotic, rapamycin, displays
potent immunosuppressive properties that are routinely em-
ployed to facilitate whole-organ transplantation. In addition
to its systemic use, however, rapamycin has been shown to
render DC profoundly protolerogenic through inhibition of
mammalian target of rapamycin (mTOR) signalling path-
ways. In the mouse, rapamycin-treated DC display pro-
foundly suppressed allostimulatory capacity in vitro and en-
hanced propensity for the induction of Foxp3+ regulatory T
(Treg) cells [11]. Furthermore, exposure to rapamycin, un-
like other immunosuppressive agents, leads to the upregu-
lation of CCR7 by both mouse and human DC and a com-
mensurate increase in responsiveness to CCL19, compatible
with their traﬃcking in vivo to regional lymph nodes [12,
13]. Furthermore, the administration of rapamycin-treated
recipient DC pulsed with donor alloantigens has secured
the indeﬁnite survival of tissue allografts in various animal
models [14–16], the resulting tolerance having been demon-
strated to rely on the expansion of antigen-speciﬁc Treg cells
[17]. Nevertheless, despite its compelling credentials, rapa-
mycin has been reported to exert quite distinct eﬀects on hu-
man DC, depending on the source and subset involved [18].
We have, therefore, investigated the compatibility of proto-
cols for the diﬀerentiation of DC from the H1 hESC line
(H1-DC) with the use of rapamycin. Here we report that
H1-DCs are peculiarly sensitive to the immunomodulatory
eﬀects of rapamycin, compared with conventional moDC, as
evidenced by the speciﬁc loss of immunogenicity and en-
hanced capacity to polarise responding T cells towards a
regulatory phenotype. Our ﬁndings provide an important
ﬁrst step towards the use of DC diﬀerentiated from hESC in
theestablishmentoftolerancetoreplacementtissues,provid-
ing a proof of concept for their future application in regener-
ative medicine.
2.MaterialsandMethods
2.1. Isolation of Primary Cells. Monocytes and na¨ ıve T
cells were isolated from peripheral blood mononuclear cells
(PBMCs) of buﬀy coats (NHS Blood Transfusion Service) or
from blood provided by volunteers under informed consent
using CD14-coated beads or na¨ ıve CD4+ T cell selection kit
(Miltenyi Biotec). Cell populations were positively selected
or depleted from PBMC using AutoMACS separation ac-
cording to the manufacturer’s instructions.
2.2. Culture of hESC. H1 ESCs were cultured in X-VIVO-10
medium (without gentamycin or phenol red, Lonza) sup-
plemented with nonessential amino acids (PAA Laboratories
GmbH), 2mM L-glutamine (PAA Laboratories GmbH),
50μM 2-mercaptoethanol (Sigma), 0.5ng/mL recombinant
human transforming growth factor β (TGF-β,R & DS y s -
tems), and 80ng/mL recombinant human basic ﬁbroblast
growth factor (bFGF, R&D Systems) on 6-well plates, pre-
viously coated with Matrigel (phenol red-free, growth fac-
tor reduced, BD Biosciences) diluted 1:30 using ice-
cold knockout Dulbecco’s Modiﬁed Eagle’s Medium (KO-
DMEM, Invitrogen). Supplemented X-VIVO-10 medium
was replaced daily except the day following passaging.
Human ESCs were routinely passaged as cell clusters of
about 0.5mm diameter every 4–6 days. For passaging, colo-
nies were incubated in ﬁlter-sterilised warm collagenase IV
(Invitrogen) until detachment of the stromal cells. Stromal
cells were removed by washing with Dulbecco’s Phosphate-
Buﬀered Saline (DPBS) and hESC were scraped oﬀ into sup-
plemented X-VIVO-10 Medium for 1:5 passaging. All cell
cultures were incubated in a humidiﬁed incubator at 37◦C
and 5% CO2.
2.3.DiﬀerentiationofhESC. H1hESCswereplatedat3 ×106
per well of 6-well ultralow attachment (ULA) plates (Costar)
i nat o t a lv o l u m eo f4m Lo fX - V I V O - 1 5m e d i u m( L o n z a ) ,
supplemented with 1mM sodium pyruvate, nonessential
amino acids, 2mM L-glutamine (all PAA Laboratories
GmbH) and 5μM 2-mercaptoethanol (Sigma). The follow-
ing growth factors were added: 50ng/mL recombinant hu-
manbonemorphogeneticprotein-4(BMP-4,R&DSystems),
50ng/mL recombinant human vascular endothelial growth
factor(VEGF,R&DSystems),20ng/mLrecombinanthuman
stem cell factor (SCF, R&D Systems), and 50ng/mL recom-
binant human granulocyte macrophage-colony stimulating
factor (GM-CSF, R&D Systems). After 2-3 days, the medium
was topped up with 2mL of fresh supplemented X-VIVO-
15 medium to produce a total volume of 6mL. Subsequent
feeding was performed every 2-3 days by replacing 2-3mL
of old medium with new supplemented X-VIVO-15 medium
from which every 5 days a growth factor was removed start-
ing with BMP-4 at day 5, followed by VEGF at day 10 and
SCF at day 15 of diﬀerentiation [19]. Once macrophage-like
cellswereobserved,25ng/mLofIL-4(Peprotech)wasadded,
which was increased stepwise to 100ng/mL.
On days 30–35, monocytes were harvested by gentle
pipetting, leaving adherent macrophages in the culture dish.
The cell suspension was passed through a 70μm cell strainer
(BD Falcon) to remove cellular debris, washed with DPBS
and plated at 1−1.5 × 106 monocytes per well of a 6-well
Cellbind plate (Corning) in X-VIVO-15 supplemented with
50ng/mL GM-CSF and 100ng/mL IL-4.
2.4. Derivation of DC from Human Monocytes. Monocytes
wereculturedinRPMI1640(Invitrogen)supplementedwithJournal of Biomedicine and Biotechnology 3
2mML-glutamine(PAAlaboratoriesGmbH),50U/mLpen-
icillin (PAA laboratories GmbH), 50μg/mL streptomycin
(PAA laboratories GmbH), 10% heat-inactivated and ﬁlter-
sterilised fetal bovine serum (FBS), 50ng/mL GM-CSF, and
100 ng/mL IL-4 on 6-well Cellbind plates for 6–8 days.
2.5. DC Maturation and Rapamycin Treatment. Two days
after monocytes were plated, monocyte-derived and hESC-
derived immature DC were treated with 10ng/mL and 5–
7ng/mL of rapamycin (Sigma), respectively. On day 5, DCs
were matured for 48hr using a maturation cocktail consist-
ing of 50ng/mL of GM-CSF (R&D Systems), 100ng/mL IL-4
(R&D Systems), 20ng/mL IFNγ (R&D Systems), 50ng/mL
TNFα (R&D Systems), 10ng/mL of IL-1β (R&D Systems),
and 1μg/mL PGE2(Sigma). On day 6-7, DCs were harvested
bygentlepipetting,passedthrougha70μmcellstrainer,cen-
trifuged, and resuspended prior to their use in experiments.
2.6. Allogeneic Mixed Leukocyte Reaction (MLR). DCs were
incubated in 10μg/mL mitomycin C (Sigma) in supplement-
ed RPMI 1640 at 37◦C for 30 minutes. Cells were washed,
resuspended in supplemented RPMI 1640, and plated in
triplicatetogiveeither2.5 ×103 cells,5 ×103 cells,or1 ×104
cells in a total volume of 100μl per well using 96-well round-
bottom plates (Corning). Na¨ ıve CD4+ T cells were plated at
5 × 104 cells per well to yield a stimulator to responder ratio
of 1:5, 1:10, and 1:20 and a total volume of 200μl/well.
Wells containing T cells and mitomycin C-treated DC alone
were included as controls for background proliferation of
either cell type. Cells were incubated for 5 days at 37◦C, after
whichTcellswerepulsedwith0.5μCi of [3H]-thymidine per
well for 18hr before harvesting.
2.7. DC-T-Cell Cocultures. DC (2 × 105)a n d1× 106 Tc e l l s
were cocultured in supplemented RPMI 1640 using 24-well
Cellbind plates (Corning). After 7 days of coculture, cells
were harvested and stained for CD4, CD25, and Foxp3 and
analysed by ﬂow cytometry as described below.
2.8. Flow Cytometry. Cells were incubated for 15min in
blockingsolution(5%normalratserum,0.5%bovineserum
albumin, and 0.1% NaN3 in DPBS) on ice. Cells were
washed with DPBS containing 1% FBS and 0.1% NaN3 and
resuspended in this solution together with one or several
of the following ﬂuorescently labelled antibodies: SSEA-4
(clone: MC-813-70, R&D Systems), eZFluor anti-human
CD4-FITC and either CD25-APC or CD25-AF488 Cocktail
(eBioscience), CD83 (HB15e, AbD Serotec), CD86 (BU63,
AbD Serotec), CD40 (LOB7/6, AbD Serotec), PD-L1 (AbD
Serotec), CD127 (40131, R&D Systems), CTLA-4 (BNI3, BD
Pharmingen), MHC II HLA-DR/DQ/DP (WR18, AbD Ser-
otec), CD80 (MEM-233, AbD Serotec), CD45 (15.2, AbD
Serotec), CD14 (MEM18, AbD Serotec), CD11c (BU15, AbD
Serotec), and CD13 (AbD Serotec). Cells were incubated at
4◦C in the dark for 30–60 minutes. For the last 10 minutes,
250ng/mL7-AADwasadded.Cellswerewashed,ﬁxedin2%
formaldehyde, and analysed by ﬂow cytometry.
Intracellular staining was performed according to the
manufacturer’s instructions using permeabilisation and ﬁx-
ation buﬀers (eBioscience) and antibodies speciﬁc for Oct-4
(240408, R&DSystems) or Foxp3 (eBioscience).
3. Results
3.1. Diﬀerentiation and Characterisation of DC from the H1
hESCLine. Inordertoinvestigatewhetherprotocolswehave
established previously for the diﬀerentiation of DC from
hESC might be compatible with the use of rapamycin, we
made use of the well-characterised H1 hESC line. In keeping
with its downstream clinical application, H1 was maintained
in serum-free medium devoid of animal products and feeder
cells, as described previously [20, 21]. Under these condi-
t i o n s ,H 1f o r m e dc o m p a c tc o l o n i e sw i t hc l e a r l yd e ﬁ n e d
boarders (Figure 1(a)), the individual cells displaying a high
nucleus:cytoplasm ratio and prominent heterochromatin.
Flow cytometric analysis revealed expression of the tran-
scription factor Oct-4 and stage-speciﬁc embryonic antigen
4 (SSEA-4), both of which are known to strongly correlate
with pluripotency (Figure 1(b)).
The diﬀerentiation of H1 was directed along the DC lin-
eage in ultralow attachment plates by exposure to a cocktail
of growth factors consisting of BMP-4, VEGF, SCF, and GM-
CSF, as described previously [19]. The initiation of hemato-
poiesis wasapparentbyday20ofculture,asevidencedbythe
appearanceofCD45+ cells,althoughthelackofexpressionof
CD13, CD14, and CD11c suggested that commitment to the
myeloidlineagehadyettooccur(Figure 2(a)).Incontrast,by
day 27 of culture, a small proportion of cells, residing within
a population expressing intermediate levels of CD45, had
upregulated these markers, consistent with their progressive
commitment to the myeloid lineage (Figure 2(b)). Indeed,
from day 28 of culture onwards, cells with the characteristic
morphology of human DC could be identiﬁed within
cultures, either as clusters with prominent veils of cytoplasm
or individual cells with long dendrites (Figure 2(c)).
By day 33 of culture, up to 21% of cells had adopted
a CD45hi phenotype, the majority of which were CD11c+
(Figure 2(d)). Whereas these cells predominantly expressed
MHC class I and CD86, CD83, and MHC class II expression
were low, consistent with the phenotype of immature DC.
Culture of H1-DC for 2 days in a cocktail of cytokines con-
sisting of GM-CSF, IL-4, IFNγ,T N F α,I L - 1 β,a n dP G E 2
induced their maturation, as evidenced by the upregulation
of CD83, similar to moDC (Figure 2(e)). Although, as previ-
ously described, MHC class II was not upregulated by H1-
DC to the same extent as their monocyte-derived counter-
parts [19], surface expression of the costimulatory molecules
CD40, CD80, and CD86 was consistent with our previous
reports of the ability of this novel source of DC to stimulate
proliferative responses among na¨ ıve allogeneic T cells [19].
3.2. Rapamycin Reduces the Immunogenicity of H1-DC. We
next investigated whether the exposure of H1-DC to rapa-
mycin could promote the acquisition of a protolerogenic
phenotype, similar to that described for other populations4 Journal of Biomedicine and Biotechnology
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Figure 1: Maintenance of the H1 hESC line. (a) Colony of H1 hESC showing the morphology typical of pluripotent stem cells, including
prominent boarders (×20 magniﬁcation). (b) Expression by H1 hESC of the transcription factor Oct-4 and the surface marker SSEA-4,
both of which correlate with pluripotency. Dead cells were removed from ﬂow cytometric analysis using 7-AAD staining. Open histograms
represent appropriate isotype controls.
of mouse and human DC [11–13]. Accordingly, we cultured
H1-DC with rapamycin for 3 days prior to inducing their
maturation with proinﬂammatory cytokines and assessed
their surface phenotype and immunostimulatory capacity in
the allogeneic MLR. Whereas the addition of 10ng/mL of
rapamycin to moDC had only a modest impact on their
viability, H1-DC proved especially sensitive to its toxicity,
undergoing signiﬁcant levels of apoptosis at concentrations
greaterthan7ng/mL,asdescribedinotherstudies[22].Nev-
ertheless, careful titration of the compound revealed that ex-
posure of H1-DC to concentrations between 5 and 7ng/mL
exerted immunomodulatory eﬀects without compromising
their viability. Interestingly, conditioning of H1-DC with
rapamycin did not appear to inhibit their maturation since
they upregulated CD83 and CD86 and maintained surface
expression of MHC class II and the inhibitory receptor PD-
L1 (Figure 3(a)), strongly implicated in the polarisation of
na¨ ıve T cells towards a Treg phenotype [23]. Signiﬁcantly,
however, H1-DC consistently failed to up-regulate CD40 fol-
lowing exposure to rapamycin, even though higher concen-
trations of the pharmacological agent had little impact on
CD40 expression by moDC (Figure 3(b)). Consistent with
their reduced levels of CD40 expression, the immunostimu-
latory capacity of rapamycin-treated H1-DC was signiﬁcant-
ly reduced in cocultures with na¨ ıve allogeneic T cells (Figure
3(c)).Incontrast,10ng/mLofrapamycinexertedonlymod-
est inhibitory eﬀects on the capacity of moDC to stimulate
proliferativeresponsesamongna¨ ıveallogeneicTcells(Figure
3(c)).
3.3.Rapamycin-TreatedH1-DCPolariseNa¨ ıveTCellstowards
aRegulatoryPhenotype. Giventhereducedimmunostimula-
tory capacity of rapamycin-treated H1-DC and their acqui-
sition of a CD40lo PD-L1+ phenotype, we next investigated
whethertheircoculturewithna¨ ıveCD4+ Tcellsmightfavour
the induction of Treg cells, deﬁned as CD4+CD25hi cells with
persistent expression of Foxp3. Although at the outset, T
cells enriched for CD4+ cells were predominantly Foxp3−
(Figure 4(a)), coculture with immature H1-DC for 7 days,
resulted in up to 8.5% of CD4+CD25hi cells retaining Foxp3
expression by the end of the culture period (Figure 4(b)).
When the H1-DC had been matured prior to coculture with
na¨ ıve allogeneic T cells, the proportion of cells committed to
theTreg celllineageincreased marginallyto 12.5%. However,
the use of H1-DC, which had been induced to mature fol-
lowing exposure to rapamycin, consistently resulted in a sig-
niﬁcant increase in the induction of Treg cells which rep-
resented approximately 26.5% of CD4+CD25hi cells, similar
results being obtained in four independent experiments. By
contrast, rapamycin conditioning of moDC exerted only a
marginal eﬀect on the ability of the cells to polarise respond-
ing T cells towards a regulatory phenotype (Figure 4(b)).
GiventhattheidentiﬁcationofbonaﬁdehumanTregcells
is confounded by the universal upregulation of CD25 by ac-
tivated T cells and their transient expression of Foxp3, irre-
spective of ﬁnal lineage commitment, we investigated wheth-
er CD25hi Foxp3+ cells appearing in such cultures displayed
other known phenotypic features of Treg cells. Cells co-
expressing CD25 and Foxp3 were found to express CTLA-
4( Figure 5(a)), while lacking expression of the α subunit
of the IL-7R, CD127 (Figure 5(b)), such a phenotype being
strongly suggestive of a regulatory function [24, 25].
4. Discussion
The development of robust protocols for the diﬀerentiation
of DC from hESC lines, derived under cGMP conditions,
oﬀers a potentially unlimited source of cells with little var-
iability between batches, which may be subjected to rigorous
quality control. The potent immunostimulatory capacity of
DCdiﬀerentiatedinthiswayhassuggestedthattheywillﬁnd
a likely application in the presentation of tumour associated
antigens to the T-cell repertoire, thereby overcoming many
of the limitations inherent in the use of moDC for cancer
immunotherapy [19]. Nevertheless, given the accumulation
of evidence in favour of an additional role played by DC in
the establishment and ongoing maintenance of immunolog-
ical tolerance [3], the availability of DC diﬀerentiated from
hESC suggests they may enjoy a broader remit. We have, for
instance,proposedthathESC-derivedDCmightbeexploitedJournal of Biomedicine and Biotechnology 5
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Figure 2: Time course of DC diﬀerentiation from H1 hESC. Cells were harvested from cultures at various time points and analysed by
ﬂow cytometry for the onset of hematopoiesis and the appearance of DC. (a) Cells harvested at day 20 of culture showing expressing of
CD45 but lack of myeloid commitment, as evidenced by staining for CD13, CD14, and CD11c. Open histograms show levels of background
staining using isotype-matched control antibodies. (b) Appearance of CD45int cells at day 27 of culture, accompanied by the upregulation
of myeloid-speciﬁc markers. (c) Photomicrograph, taken at day 28 of culture, showing the morphology of DC, including veils of cytoplasm
and long dendrites (inset) (×40 magniﬁcation). (d) Cells harvested at day 33 of culture, showing the appearance of a CD45hi population
containing predominantly DC progenitors expressing CD14, CD11c, CD86 and MHC class I. (e) Phenotype of immature and mature H1-
DCs compared with human moDC. DCs were cultured either in medium alone or medium supplemented with the maturation cocktail and
stained for MHC class II, the maturation marker CD83 and classical costimulatory molecules. Dead cells were excluded from the analysis
using 7-AAD. Dashed histograms show the phenotype of immature DCs while the ﬁlled histograms represent mature DCs. Open histograms
depict background staining using isotype-matched controls.
to induce tolerance to the alloantigens they express, thereby
conditioning recipients to accept replacement tissues diﬀer-
entiated from the same parent cell line [7]. This prospect is,
however, contingent on the development of clinically com-
pliantstrategiestoensurethestabletolerogenicityofDCgen-
eratedinthisway.Whiletheintroductionoftransgenes,such
as PD-L1, at the ESC stage might confer on the resulting DC
an immunomodulatory function [8], the additional regula-
tory hurdles encountered by the administration to patients
of genetically modiﬁed cells, has fuelled attempts to identify
approved pharmacological agents that coerce DC to adopt a
protolerogenic phenotype [10].
Rapamycin is one such agent routinely exploited for its
immunosuppressive properties in the treatment of allograft
rejectionbutwhichhasbeenshowntoexertaprofoundeﬀect
on the function of individual components of the immune
system, including DC. Indeed, treatment of DC with rapa-
mycin in vitro has been demonstrated to arrest them in an
immature or semimature state rendering them tolerogenic
[11–13]. Accordingly, in various preclinical transplantation
models, administration of rapamycin-treated recipient DC,
pulsed with a source of donor alloantigens, secured the long-
termsurvivaloforganallografts[14–16].Ifsuchacondition-
ing regime could be applied to DC diﬀerentiated from hESC,
it may prove feasible to establish operational tolerance to the
alloantigens they endogenously express, in advance of CRT.
As a ﬁrst step towards this goal, we have demonstrated the
sensitivity of H1-DC to rapamycin which signiﬁcantly re-
duces their immunostimulatory properties in the allogeneic
MLR (Figure 3(b)), an in vitro correlate of the direct path-
way of alloantigen presentation. Furthermore, rapamycin
substantially augments their ability to polarise responding
CD4+ T cells towards a regulatory phenotype (Figure 4(b)),
as determined by their sustained expression of Foxp3 and
adoptionofaCTLA4+CD127− phenotype.Furthermore,our
preliminaryresultsindicatethat,whilematurationofH1-DC
induces secretion of high levels of the inﬂammatory cytokine
IL-6 [19], prior exposure to rapamycin signiﬁcantly reduces
IL-6 production, possibly guiding responding T cells away
from Th1/Th17 commitment towards a Treg phenotype.
These results strongly suggest, therefore, that rapamycin may
have the desirable properties of preventing activation of
alloreactiveTcellsthroughboth thedirect andindirect path-
ways of alloantigen presentation, the induction of Treg cells
potentially modulating responsiveness to indirectly present-
ed alloantigens that have been reprocessed by endogenous
recipient DC. In contrast to our ﬁndings with H1-DC,
rapamycin-treatment of moDC had only a modest impact
on their immunostimulatory capacity and little eﬀect on
their surfacephenotype. Although our results are contrary toJournal of Biomedicine and Biotechnology 7
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Figure 3: Eﬀect of rapamycin (Rapa) on the phenotype and function of H1-DC. DCs were either untreated, matured in response to the
maturation cocktail or treated with Rapa for 3 days prior to maturation. (a) H1-DC stained for the expression of the maturation marker
CD83, the costimulatory molecules CD86 and CD40, as well as the inhibitory receptor PD-L1. Dead cells were excluded from analysis
using 7-AAD. Open histograms represent the level of background staining using appropriate isotype-matched controls. Data from one
of 3 independent experiments are shown. (b) Phenotypic analysis of control populations of moDC treated and stained in parallel with
rapamycin. (c) Eﬀect of rapamycin on the allostimulatory capacity of DC in the allogeneic MLR. DCs were mitotically-inactivated using
mitomycin C and plated in triplicate at a top dose of 104 cells per well of a 96-well round-bottomed plate; na¨ ıve CD4+ T cells were plated at
5 × 104 cells/well. Cells were incubated for 5 days before pulsing with 3H-thymidine overnight. Graphs show the mean of triplicate cultures
±S.D. Data are shown from one experiment, representative of 3 independent experiments.
some other reports [12,18], manystudies havetypicallyused
higherconcentrationsofrapamycinandregimesforthemat-
uration of moDC involving exposure to bacterial products,
such as lipopolysaccharide, which target diﬀerent intracel-
lular signalling pathways from those solicited upon culture
with the cocktail of proinﬂammatory cytokines used in these
studies.
Despite the profound eﬀect that rapamycin exerts on the
functional potential of H1-DC, phenotypic analysis of cells
treated with the compound was largely unremarkable, with
the exception that upregulation of the costimulatory mole-
culeCD40uponmaturationwaspreventedbypriorexposure
to the compound. The signiﬁcance of these ﬁndings may lie
in the growing appreciation of the role played by CD40 as8 Journal of Biomedicine and Biotechnology
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Figure 4: Enhanced capacity of rapamycin-treated H1-DC to promote Treg induction. (a) The starting population of naive CD4+ Tc ell sw a s
analysed by ﬂow cytometry for the expression of CD25 and Foxp3, markers associated with commitment of T cells to the regulatory T cell
lineage. (b) Rapamycin enhances the capacity of H1-DC to induce Treg cells compared to moDC. DCs were either untreated, matured with
the maturation cocktail or treated with rapamycin for 3 days prior to maturation. DCs were harvested, washed, and plated at 2 × 105 per
well with 106 naive CD4+ T cells per well of a 24-well plate to yield a ratio of DC:T cells of 1:5. On day 7, cocultures were stained for CD4,
CD25, and Foxp3 and analysed. Dead cells were excluded from the analysis using 7-AAD staining. Data from one experiment representative
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Figure 5: Phenotypic characterisation of putative CD25hi Foxp3+ Treg cells from cocultures of DC and na¨ ıve T cells. The CD25hi Foxp3+
population expresses CTLA-4 (a) but lacks expression of CD127 in comparison with control Foxp3− T cells (b), consistent with the reported
phenotype of bona ﬁde Treg cells.
the fulcrum on which the balance between tolerance and im-
munity has been shown to pivot. For instance, the admin-
istration to mice of CD40−/− DC laden with foreign antigen
wasshowntoinduceprofoundantigen-speciﬁctoleranceup-
on subsequent immunization, results which are consistent
with the induction of a repertoire of Treg cells [26]. Further-
more, in mice receiving foreign antigen chemically conjugat-
ed to CD205-speciﬁc mAb as a way of delivering antigen to
DC in the steady state, the induction of tolerance could be
abrogated in favour of systemic immunity by the concomi-
tant administration of agonistic antibodies speciﬁc for CD40
[4].
It is the central role played by CD40 in a transplanta-
tion setting that underlies the success of strategies for inter-
vening in allograft rejection based on the blockade of CD40-
CD154 interactions [27]. Although unanticipated compli-
cations associated with the use of mAb speciﬁc for CD154
have hindered the application of such a strategy to the clinic;
the long-term acceptance of allografts in mice was found to
bear the distinctive features of regulation, including linked
suppressionandinfectioustolerance[28,29].Aconditioning
regime that limits the delivery of CD40 signalling by do-
nor DC might, therefore, be anticipated to predispose recip-
ients towards tolerance based on the generation of a reper-
toire of alloantigen-speciﬁc Treg cells. Indeed, the level of
expression of CD40 has been shown to be critical in deter-
mining the outcome of antigen recognition in a model of
Leishmania donovani infection, high levels of expression in-
ducing eﬀector T cells, low levels favouring polarisation to-
wards a Treg phenotype [30]. Furthermore, blockade of the
CD40-CD154 axis in combination with rapamycin was
shown to achieve tolerance even across a xenogeneic barrier
[31]. Although the mechanisms involved were not speciﬁ-
cally elucidated in this study, it may be signiﬁcant in our own
experiments that PD-L1 expression by H1-DC was unaﬀect-
ed by rapamycin treatment, being upregulated in response
to maturation stimuli, irrespective of prior exposure to the
compound. Given the essential role described for PD-L1 in
polarisation of na¨ ıve T cells towards a Treg cell phenotype
[23], it is tempting to speculate that it is by altering the
critical balance between costimulatory and inhibitory signals
delivered by H1-DC, that rapamycin treatment strongly
favours a tolerogenic proﬁle.
5. Conclusions
We have demonstrated previously that hESC may be diﬀer-
entiated into populations of immunogenic DC whose prop-
ertiesmaybe exploitedinregimesofcancerimmunotherapy.
Here,weextendthisparadigmbyshowingthatourprotocols
are fully compliant with the use of rapamycin which favours
a protolerogenic phenotype of the resulting DC. Our results
pave the way for the future use of rapamycin-conditioned
hESC-derived DC in regimes for the induction of tolerance,
as a prelude to CRT.
Conﬂict of Interests
A. Reddy and K. P. Nishimoto declare a potential ﬁnancial
conﬂict of interests as employees of Geron Corporation.10 Journal of Biomedicine and Biotechnology
Acknowledgments
The authors are grateful to Tim Davies, Naoki Ichiryu, and
Simon Hackett for helpful discussions and to Lara Whitmore
for administrative assistance. A. J. Leishman is the recipient
of an MRC capacity building studentship, awarded to the
Oxford Stem Cell Institute. This work was performed under
a sponsored research agreement between the University of
Oxford and Geron Corporation, with additional support
from the Medical Research Council UK, in the form of Grant
G0802538 awarded to P. J. Fairchild.
References
[1] I. Klimanskaya, N. Rosenthal, and R. Lanza, “Derive and con-
q u e r :s o u r c i n ga n dd i ﬀerentiating stem cells for therapeutic
applications,” Nature Reviews Drug Discovery,v o l .7 ,n o .2 ,p p .
131–142, 2008.
[2] P.J.Fairchild,N.J.Robertson,S.L.Minger,andH.Waldmann,
“Embryonic stem cells: protecting pluripotency from alloreac-
tivity,”CurrentOpinioninImmunology,vol.19,no.5,pp.596–
602, 2007.
[3] R.M.SteinmanandJ.Banchereau,“Takingdendriticcellsinto
medicine,” Nature, vol. 449, no. 7161, pp. 419–426, 2007.
[4] D. Hawiger, K. Inaba, Y. Dorsett et al., “Dendritic cells induce
peripheral T cell unresponsiveness under steady state condi-
tions in vivo,” Journal of Experimental Medicine, vol. 194, no.
6, pp. 769–779, 2001.
[5] S. F. Yates, A. M. Paterson, K. F. Nolan et al., “Induction of
regulatoryTcellsanddominanttolerancebydendriticcellsin-
capableoffullactivation,” Journal of Immunology, vol.179,no.
2, pp. 967–976, 2007.
[6] M. V. Dhodapkar, R. M. Steinman, J. Krasovsky, C. Munz, and
N. Bhardwaj, “Antigen-speciﬁc inhibition of eﬀector T cell
function in humans after injection of immature dendritic
cells,” Journal of Experimental Medicine, vol. 193, no. 2, pp.
233–238, 2001.
[7] P. J. Fairchild, S. Cartland, K. F. Nolan, and H. Waldmann,
“Embryonic stem cells and the challenge of transplantation
tolerance,” Trends in Immunology, vol. 25, no. 9, pp. 465–470,
2004.
[ 8 ]S .S e n j u ,H .S u e m o r i ,H .Z e m b u t s ue ta l . ,“ G e n e t i c a l l ym a n i -
pulated human embryonic stem cell-derived dendritic cells
with immune regulatory function,” Stem Cells, vol. 25, no. 11,
pp. 2720–2729, 2007.
[9] S. Hirata, S. Senju, H. Matsuyoshi, D. Fukuma, Y. Uemura,
and Y. Nishimura, “Prevention of experimental autoimmune
encephalomyelitis by transfer of embryonic stem cell-derived
dendriticcellsexpressingmyelinoligodendrocyteglycoprotein
peptide along with TRAIL or programmed death-1 ligand 1,”
Journal of Immunology, vol. 174, no. 4, pp. 1888–1897, 2005.
[10] A. J. Leishman, K. M. Silk, and P. J. Fairchild, “Pharmacologi-
cal manipulation of dendritic cells in the pursuit of transplan-
tation tolerance,” Current Opinion in Organ Transplantation,
vol. 16, no. 4, pp. 372–378, 2011.
[11] H. R. Turnquist, G. Raimondi, A. F. Zahorchak, R. T. Fischer,
Z. Wang, and A. W. Thomson, “Rapamycin-conditioned den-
dritic cells are poor stimulators of allogeneic CD4+ Tc e l l s ,b u t
enrich for antigen-speciﬁc Foxp3+ T regulatory cells and pro-
mote organ transplant tolerance,” Journal of Immunology, vol.
178, no. 11, pp. 7018–7031, 2007.
[12] V. Sordi, G. Bianchi, C. Buracchi et al., “Diﬀerential eﬀects of
immunosuppressive drugs on chemokine receptor CCR7 in
human monocyte-derived dendritic cells: selective upregula-
tion by rapamycin,” Transplantation, vol. 82, no. 6, pp. 826–
834, 2006.
[13] W. Reichardt, C. D¨ urr, D. Von Elverfeldt et al., “Impact of
mammaliantargetofrapamycininhibitiononlymphoidhom-
ing and tolerogenic function of nanoparticle-labeled dendritic
cells following allogeneic hematopoietic cell transplantation,”
Journal of Immunology, vol. 181, no. 7, pp. 4770–4779, 2008.
[14] J. M. Sacks, Y. R. Kuo, A. Taieb et al., “Prolongation of com-
posite tissue allograft survival by immature recipient dendritic
cellspulsedwithdonorantigen andtransientlow-doseimmu-
nosuppression,” Plastic and Reconstructive Surgery, vol. 121,
no. 1, pp. 37–49, 2008.
[15] R. Ikeguchi, J. M. Sacks, J. V. Unadkat et al., “Long-term sur-
vival of limb allografts induced by pharmacologically con-
ditioned, donor alloantigen-pulsed dendritic cells without
maintenance immunosuppression,” Transplantation, vol. 85,
no. 2, pp. 237–246, 2008.
[16] T. Taner, H. Hackstein, Z. Wang, A. E. Morelli, and A. W.
Thomson, “Rapamycin-treated, alloantigen-pulsed host den-
dritic cells induce Ag-speciﬁc T cell regulation and prolong
graft survival,” American Journal of Transplantation, vol. 5, no.
2, pp. 228–236, 2005.
[17] E. K. Horibe, J. Sacks, J. Unadkat et al., “Rapamycin-condi-
tioned, alloantigen-pulsed dendritic cells promote indeﬁnite
survival of vascularized skin allografts in association with T
regulatorycellexpansion,”TransplantImmunology,vol.18,no.
4, pp. 307–318, 2008.
[18] M. Haidinger, M. Poglitsch, R. Geyeregger et al., “A versatile
role of mammalian target of rapamycin in human dendritic
cell function and diﬀerentiation,” Journal of Immunology, vol.
185, no. 7, pp. 3919–3931, 2010.
[19] S. Y. Tseng, K. P. Nishimoto, K. M. Silk et al., “Generation of
immunogenic dendritic cells from human embryonic stem
cells without serum and feeder cells,” Regenerative Medicine,
vol. 4, no. 4, pp. 513–526, 2009.
[20] C. Xu, M. S. Inokuma, J. Denham et al., “Feeder-free growth
of undiﬀerentiated human embryonic stem cells,” Nature
Biotechnology, vol. 19, no. 10, pp. 971–974, 2001.
[21] Y. Li, S. Powell, E. Brunette, J. Lebkowski, and R. Mandalam,
“Expansion of human embryonic stem cells in deﬁned serum-
free medium devoid of animal-derived products,” Biotechnol-
ogy and Bioengineering, vol. 91, no. 6, pp. 688–698, 2005.
[22] A. M. Woltman, J. W. De Fijter, S. W. A. Kamerling et al.,
“Rapamycin induces apoptosis in monocyte- and CD34-de-
rived dendritic cells but not in monocytes and macrophages,”
Blood, vol. 98, no. 1, pp. 174–180, 2001.
[23] L. Wang, K. Pino-Lagos, V. C. De Vries, I. Guleria, M. H.
S a y e g h ,a n dR .J .N o e l l e ,“ P r o g r a m m e dd e a t h1l i g a n ds i g n a l -
ing regulates the generation of adaptive Foxp3+CD4+ regula-
tory T cells,” Proceedings of the National Academy of Sciences of
the United States of America, vol. 105, no. 27, pp. 9331–9336,
2008.
[24] N. Seddiki, B. Santner-Nanan, J. Martinson et al., “Expression
of interleukin (IL)-2 and IL-7 receptors discriminates between
humanregulatoryandactivatedTcells,”JournalofExperimen-
tal Medicine, vol. 203, no. 7, pp. 1693–1700, 2006.
[25] W. Liu, A. L. Putnam, Z. Xu-yu et al., “CD127 expression in-
versely correlates with FoxP3 and suppressive function of
human CD4+ Tr e gc e l l s , ”Journal of Experimental Medicine,
vol. 203, no. 7, pp. 1701–1711, 2006.
[26] K. Hochweller and S. M. Anderton, “Systemic administra-
tion of antigen-loaded CD40-deﬁcient dendritic cells mimicsJournal of Biomedicine and Biotechnology 11
soluble antigen administration,” European Journal of Immu-
nology, vol. 34, no. 4, pp. 990–998, 2004.
[ 2 7 ]C .P .L a r s e n ,E .T .E l w o o d ,D .Z .A l e x a n d e re ta l . ,“ L o n g - t e r m
acceptance of skin and cardiac allografts after blocking CD40
and CD28 pathways,” Nature, vol. 381, no. 6581, pp. 434–438,
1996.
[28] K. Honey, S. P. Cobbold, and H. Waldmann, “CD40 ligand
blockade induces CD4+ T cell tolerance and linked suppres-
sion,” Journal of Immunology, vol. 163, no. 9, pp. 4805–4810,
1999.
[29] L. Graca, K. Honey, E. Adams, S. P. Cobbold, and H. Wald-
mann, “Cutting edge: anti-CD154 therapeutic antibodies in-
duce infectious transplantation tolerance,” Journal of Immu-
nology, vol. 165, no. 9, pp. 4783–4786, 2000.
[30] S. Martin, R. Agarwal, G. Murugaiyan, and B. Saha, “CD40
expression levels modulate regulatory T cells in Leishmania
donovani infection,” Journal of Immunology, vol. 185, no. 1,
pp. 551–559, 2010.
[ 3 1 ]Y .D .M u l l e r ,G .M a i ,P .M o r e le ta l . ,“ A n t i - C D 1 5 4m A Ba n d
rapamycin induce T regulatory cell mediated tolerance in rat-
to-mouseislettransplantation,”PLoSOne,vol.5,no.4,Article
ID e10352, 2010.